Skip to content

AbCellera Biologics

US · ABCL #2215 by market cap Listed 2020
9.69 -0.78 -7.45%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Price chart

Pre-market 9.96 -4.87%
After-hours 9.73 +0.41%
Overnight 10.28 -1.81%
14.825.099.692026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ABCL?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +84.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 9.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth B-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) -46.3% Better than 1%
Net income CAGR (3Y) 691.9% Better than 100%
Profitability C-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 100.0% Better than 99%
Operating margin -270.5% Better than 5%
Net margin -194.9% Better than 5%
Return on equity -14.5% Better than 17%
Return on invested capital -15.2% Better than 15%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -14.4% Better than 41%
6-month return 86.3% Better than 99%
12-month return (ex latest month) 236.8% Better than 99%
Distance below 52-week high 35.5% Better than 34%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 11.3x Better than 94%
Debt to assets 10.6% Better than 69%
Interest coverage 60.1x Better than 91%
Free cash flow / net income 129.1% Better than 57%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 88.9% Better than 72%
Upside to average target 99.5% Better than 83%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -15.67%
1M -17.25%
3M -16.25%
6M +112.04%
YTD +183.33%
1Y +184.16%
3Y +110.65%
5Y -38.67%

Key statistics

Price & volume

Prev close
10.47
Open
10.14
Day range
9.58 - 10.26
Avg price
9.86
Volume
4.25M
Turnover
41.88M
Amplitude
6.50%
52-week range
2.75 - 15.02

Valuation

P/E
-19.78
P/E (TTM)
-20.19
P/B
2.98
EPS
-0.49
Net profit
-160.04M
Net assets
1.06B

Share structure

Market cap
3.16B
Float cap
2.17B
Shares out
326.62M
Float shares
224.45M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-12-11
52-week range 57% of range
2.75 15.02

35.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-24.73M net over the window

Short interest

Shares short
29.02M
As of
2026-10-30

Frequently asked questions

What is the current stock price of AbCellera Biologics (ABCL)?

AbCellera Biologics last traded at 9.69. This page shows a periodic quote snapshot. Check the displayed quote time.

What is AbCellera Biologics's market cap?

About 3.16B.

What is the P/E ratio of AbCellera Biologics?

The trailing twelve-month P/E is -20.19. The Valuation tab shows it against the stock's own five-year range.

Does AbCellera Biologics pay a dividend?

AbCellera Biologics does not currently pay a regular dividend.

Is AbCellera Biologics a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 19.33, which implies 99.5% upside from the current price. This is not investment advice.

What is AbCellera Biologics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates AbCellera Biologics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:59:30 · For reference only, not investment advice and not tailored to your situation.

AbCellera Biologics discussion 0 comments

Add a comment